Assignee
PHILOGEN SPA
IT·34 granted patents·26 pending applications·97 citations·filing 1997–2023
Top patents by PatentIndex Score
60 records- 0190US10308696B2IL2 and TNF immunoconjugatesPHILOGEN SPA·Filed 2016·Granted Jun 4, 2019·12 cites·20 claims
- 0287US7968685B2Antibodies against Tenascin-CPHILOGEN SPA·Filed 2005·Granted Jun 28, 2011·24 cites·14 claims
- 0383US9446124B2Targeting of bone marrow neovasculaturePHILOGEN SPA·Filed 2014·Granted Sep 20, 2016·3 cites·7 claims
- 0481US9181347B2Antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2013·Granted Nov 10, 2015·4 cites·20 claims
- 0581US7851599B2Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabinePHILOGEN SPA·Filed 2007·Granted Dec 14, 2010·10 cites·20 claims
- 0680US11872288B2TNF-alpha immunoconjugate therapy for the treatment of brain tumorsPHILOGEN SPA·Filed 2021·Granted Jan 16, 2024·2 cites·16 claims
- 0779US9896503B2Antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2015·Granted Feb 20, 2018·2 cites·21 claims
- 0878US9198979B2Thiazolidine linker for the conjugation of drugs to antibodiesPHILOGEN SPA·Filed 2013·Granted Dec 1, 2015·10 cites·10 claims
- 0972US9695232B2Anti-ED-A immunoconjugates for inflammatory bowel diseasePHILOGEN SPA·Filed 2012·Granted Jul 4, 2017·2 cites·11 claims
- 1072US7273924B1Antibodies to the ED-B domain of fibronectin, their construction and usesPHILOGEN SPA·Filed 1997·Granted Sep 25, 2007·24 cites·27 claims
- 1171US11351257B2Antibody compositionsPHILOGEN SPA·Filed 2017·Granted Jun 7, 2022·1 cites·22 claims
- 1271US9096670B2Antibodies of the ED-B domain of fibronectin, their construction and usesPHILOGEN SPA·Filed 2013·Granted Aug 4, 2015·1 cites·18 claims
- 1369US10647760B2Antibodies for treatment and diagnosis of inflammatory bowel diseasePHILOGEN SPA·Filed 2016·Granted May 12, 2020·1 cites·7 claims
- 1467US12023381B2Antibody compositionsPHILOGEN SPA·Filed 2022·Granted Jul 2, 2024·0 cites·20 claims
- 1566US2015010498A1Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic AgentsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 1663US12377161B2TNF-alpha immunoconjugate therapy for the treatment of brain tumorsPHILOGEN SPA·Filed 2023·Granted Aug 5, 2025·0 cites·16 claims
- 1763US2011020224A1Apparatus and method for preparing medicines containing radioactive substancesPHILOGEN SPA·Filed 2009·Application pending·0 cites
- 1863US2025368738A1Anti-cd28 antibodiesPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 1963US2026069660A1Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancerPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 2062US11274133B2IL2 and TNF immunoconjugatesPHILOGEN SPA·Filed 2019·Granted Mar 15, 2022·0 cites·18 claims
- 2161US2025073239A1Combination of an immunocytokine comprising il-12 and a kinase inhibitorPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 2261US2015030536A1Antigen associated with lung cancers and lymphomasPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 2361US2021369857A1Il2 and tnf mutant immunoconjugatesPHILOGEN SPA·Filed 2021·Application pending·0 cites
- 2460US2019352384A1Antigen associated with rheumatoid arthritisPHILOGEN SPA·Filed 2019·Application pending·0 cites
- 2559US10385121B2Antigen associated with rheumatoid arthritisPHILOGEN SPA·Filed 2016·Granted Aug 20, 2019·0 cites·38 claims
- 2659US9289470B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartPHILOGEN SPA·Filed 2014·Granted Mar 22, 2016·0 cites·29 claims
- 2758US2013266511A1Novel antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2013·Application pending·0 cites
- 2857US11103592B2IL2 and TNF mutant immunoconjugatesPHILOGEN SPA·Filed 2017·Granted Aug 31, 2021·0 cites·13 claims
- 2957US10858411B2IL22 immunoconjugatesPHILOGEN SPA·Filed 2019·Granted Dec 8, 2020·0 cites·14 claims
- 3057US2014377780A1Vascular Tumor MarkersPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3156US2025170262A1Il2 immunoconjuqate preparationPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 3256US2025161475A1Tnfalpha immunoconjugate preparationPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 3355US2014348784A1Compositions and methods for treatment of angiogenesis in pathological lesionsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3454US10112992B2Antigens associated with endometriosis, psoriatic arthritis and psoriasisPHILOGEN SPA·Filed 2016·Granted Oct 30, 2018·0 cites·11 claims
- 3554US7109301B1Tenascin-C isoform as marker for neoplasiasPHILOGEN SPA·Filed 2000·Granted Sep 19, 2006·1 cites·12 claims
- 3654US2014341844A1Immunocytokines in combination with anti-erbb antibodies for the treatment of cancerPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3754US2024199762A1Anti-fibroblast activation protein antibodiesPHILOGEN SPA·Filed 2022·Application pending·0 cites
- 3852US10906963B2Non-glycosylated anti-tenascin antibodyPHILOGEN SPA·Filed 2017·Granted Feb 2, 2021·0 cites·21 claims
- 3952US2013108581A1Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic AgentsPHILOGEN SPA·Filed 2012·Application pending·0 cites
- 4051US10239939B2Anti-ED-A immunoconjugates for inflammatory bowel diseasePHILOGEN SPA·Filed 2017·Granted Mar 26, 2019·0 cites·16 claims
- 4151US2009028793A1Vascular Tumor MarkersPHILOGEN SPA·Filed 2007·Application pending·0 cites
- 4249US11390666B2Vascular endothelial growth factor/anti-fibronectin antibody fusion proteinsPHILOGEN SPA·Filed 2018·Granted Jul 19, 2022·0 cites·4 claims
- 4349US10125190B2Anti-collagen antibodies for treatment and diagnosisPHILOGEN SPA·Filed 2015·Granted Nov 13, 2018·0 cites·15 claims
- 4448US2023285585A1Treatment of pulmonary hypertensionPHILOGEN SPA·Filed 2021·Application pending·0 cites
- 4547US12173044B2EDB targeting IL-12 compositionsPHILOGEN SPA·Filed 2019·Granted Dec 24, 2024·0 cites·13 claims
- 4647US10246502B2IL22 immunoconjugatesPHILOGEN SPA·Filed 2017·Granted Apr 2, 2019·0 cites·15 claims
- 4747US10202442B2Antigen associated with lung cancers and lymphomasPHILOGEN SPA·Filed 2016·Granted Feb 12, 2019·0 cites·26 claims
- 4847US10098976B2Antibodies for treatment and diagnosisPHILOGEN SPA·Filed 2015·Granted Oct 16, 2018·0 cites·20 claims
- 4944US2016200789A1Il4 conjugated to antibodies against extracellular matrix componentsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 5043US11629199B2Antibodies to tumour antigensPHILOGEN SPA·Filed 2018·Granted Apr 18, 2023·0 cites·14 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PHILOGEN SPA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →